Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
21. November 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates...
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
25. September 2024 07:07 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its...
Global Virus Network’s Annual Meeting Fortifies Bonds on the African Continent to Catalyze Innovative Research, Strengthen Pandemic Preparedness, and Combat Scientific Misinformation
18. September 2024 11:15 ET
|
Global Virus Network
DURBAN, South Africa, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Global Virus Network concluded its annual meeting of closed scientific sessions held 16-18 September 2024 with a press conference....
CORRECTION: The Global Virus Network (GVN) Escalates MPOX Emergency Response Across Africa and Beyond
02. September 2024 00:47 ET
|
Global Virus Network
TAMPA, Fla., Sept. 02, 2024 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated on August 16th. Sten Vermund's full title was corrected to Sten Vermund, MD, PhD, GVN...
CORRECTION: The Global Virus Network Bolsters Multinational Mpox Response Through Critical Meeting of Key Global Partners
31. August 2024 13:51 ET
|
Global Virus Network
Last week’s meeting marked a prelude to GVN’s international meeting in Durban, South Africa, September 16-18, 2024 TAMPA, Fla., Aug. 31, 2024 (GLOBE NEWSWIRE) -- A correction has been issued for...
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
29. August 2024 18:53 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics...
The Global Virus Network Bolsters Multinational Mpox Response Through Critical Meeting of Key Global Partners
29. August 2024 11:48 ET
|
Global Virus Network
Last week’s meeting marked a prelude to GVN’s international meeting in Durban, South Africa, September 16-18, 2024TAMPA, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- To mitigate the mpox outbreak,...
Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
21. August 2024 09:00 ET
|
GeoVax, Inc.
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
19. August 2024 17:10 ET
|
Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
The Global Virus Network (GVN) Escalates MPOX Emergency Response Across Africa and Beyond
16. August 2024 09:46 ET
|
Global Virus Network
TAMPA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- As the World Health Organization (WHO) declares MPOX a public health emergency of international concern, the Global Virus Network (GVN), headquartered at...